DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Companies / Oricell Therapeutics
Oricell Therapeutics
Series D+US
Facts
- Year of incorporation
- unknown
- Revenue range (Form D)
- unknown
- Rounds on record
- 2
- Disclosed raised
- $180Msum of rounds with a disclosed amount only
- Named investors
- 7
Financing history
2 rounds
- Apr 9, 2026Pre-IPO · $110M (disclosed)Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies”
- Jan 12, 2026Series C · $70.0M (disclosed)Beijing Medical (lead)Health Care Industry Investment Fund (lead)Qiming Venture Partners (lead)E-Town Capital (participant)Elikon Venture (participant)NGS Super (participant)Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies”
Investors on record
10 edges
- Vivo Capital, LLC portfolio listing Fact vivocapital.com
- Beijing Medical round, lead Fact prnewswire.com
- Health Care Industry Investment Fund round, lead Fact prnewswire.com
- Vivo Capital, LLC round, lead Fact prnewswire.com
- Beijing Medical round, lead Fact prnewswire.com
- E-Town Capital round, participant Fact prnewswire.com
- Elikon Venture round, participant Fact prnewswire.com
- Health Care Industry Investment Fund round, lead Fact prnewswire.com
- NGS Super round, participant Fact prnewswire.com
- Qiming Venture Partners round, lead Fact prnewswire.com
People
0 officers, 0 directors
No officer or director on record.
Timeline
2
- Apr 9, 2026Oricell Therapeutics announced Pre-IPO of $110,000,000, led by Vivo Capital, Beijing Medical, Health Care Industry Investment FundRound announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
- Jan 12, 2026Oricell Therapeutics announced Series C of $70,000,000, led by Beijing Medical, Health Care Industry Investment Fund, Qiming Venture PartnersRound announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
3 observations
Every observation on this company
- Listed on portfolio page: Vivo Capital, LLC Sep 16, 2026 Fact Venture organization websites (about, team, portfolio, thesis, news pages)
- Round announced: Pre-IPO $110,000,000 Apr 9, 2026 Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
- Round announced: Series C $70,000,000 Jan 12, 2026 Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)